Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14314342 | 0.94 | EPHX2 (0.42) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL31180103 | 0.87 | HPGD (0.47) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL14314348 | 0.86 | USP2 (0.44) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL2398369 | 0.85 | USP2 (0.59) | USP2SMN1; SMN2EPHX2CTSKALDH1A1 | |
| SCHEMBL14306563 | 0.84 | HPGD (0.43) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL3665241 | 0.84 | HPGD (0.43) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL648469 | 0.84 | HPGD (0.41) | USP2SMN1; SMN2EPHX2MEN1ALDH1A1 | |
| SCHEMBL14314343 | 0.83 | HRH3 (0.40) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL14314344 | 0.82 | USP2 (0.41) | USP2SMN1; SMN2EPHX2CTSKMEN1 | |
| SCHEMBL994040 | 0.82 | USP2 (0.55) | USP2SMN1; SMN2EPHX2CTSKMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-8541573-B2 | Substituted sulfonamide compounds | GRUENENTHAL GMBH (DE) | 2013-09-24 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| US-20090298812-A1 | Substituted Sulfonamide Compounds | GRUENENTHAL GMBH (DE) | 2009-12-03 | — | — | US | disclosed |
| WO-2009109364-A1 | SUBSTITUTED SULFONAMIDE DERIVATIVES | Grünenthal GmbH (DE) | 2009-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090298812-A1 | Substituted Sulfonamide Compounds | BDKRB1, BDKRB2, TRPV1 | USP2 3796/4885SMN1; SMN2 1173/4885EPHX2 1420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.